LTGO · NASDAQ · Medical - Pharmaceuticals

Latigo Biotherapeutics (LTGO)

Develops non-opioid NaV1.8 inhibitors for acute and chronic pain.

$19.90
vs last close−0.92 (−4.44%)

Not reported.